Publications & presentations

  . 2015 . 2014 . 2013 . 2012  . 2011

2015

Publications

  1. Marzolini C, Sabin C, Raffi F, Siccardi M, Mussini C, Launay O, Burger D, Roca B, Fehr J, Bonora S, Mocroft A, Obel N, Dauchy F, Zangerle R, Gogos C, Gianotti N, Ammassari A, Torti C, Ghosn J,Chêne G, Grarup J, Battegay M for the Efavirenz and Obesity Project Team on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adules. AIDS. 2015;29:193-200. [PubMed]
  2. Mansfeld M, Skrahina A, Shepherd L, Schultze A, Panteleev AM, Miller RF, Miro JM, Zeltina I, Tetradov S, Furrer H, Kirk O, Grzeszczuk A, Bolokadze N, Matteelli A, Post FA, Lundgren JD, Mocroft A, Efsen A, Podlekareva DN on behalf of the TB:HIV Study Group in EuroCoord. Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe. HIV Med. 2015. [Epub ahead of print]
  3. Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Daumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Gunthard HF, Brun-Vezinet F, Paredes R, Metzner KJ. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. J Antimicrob Chemother. 2015;70:930-940. [Article]
  4. Jarrin I, Pantazis N, Dalmau J, Phillips AN, Olson A, Mussini C, Boufassa F, Costagliola D, Porter K, Blanco J, Del Amo J, Martiniez-Picadoo J for CASCADE Collaboration in EuroCoord. Does rapid HIV disease progression prior to cART hinder optimal CD4+ T-cell recovery once HIV-1 supression is achieved? AIDS 2015. In press.
  5. Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, Karpov I, Galli M, Domkingo P, Kirk O, Lundgren JD, Mocroft A, for EuroSIDA in EuroCoord. Liver-related death among HIV/HCV coinfected individuals, implications for the era of directly anitvirals. AIDS 2015;29:1205-1215. [PubMed]
  6. Harrison L, Melvin A, Fiscus S, Saidi Y, Nastouli E, Harper L, Compagnucci A, Babiker A, McKinney R, Gibb D, Tudor-Williams G for the PENPACT-1 (PENTA 9PACTG 390) Study Team. HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds. JAIDS. 2015;70:42-53. [Abstract]
  7. Boesecke C, Grint D, Soriano V, Lundgren JD, d'Arminio Monforte A, Mitsura VM, Chentsova N, Hadziosmanovic V, Kirk O, Mocroft A, Peters L, Rockstroh JK for EuroSIDA in EuroCoord. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected. Liver Int. 2015. [Epub ahead of print]
  8. Podlekareva D, Grint D, Karpov I, Rakmanova A, Mansinho K, Chentsova N, Zeltina I, Losso M, Parczewski M, Lundgren JD, Mocroft  A, Kirk O for EuroSIDA in EuroCoord. Changing utilitzation of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study. HIV Med. 2015. [Epub ahead of print]
  9. Schultze A, Phillips AN, Paredes R, Battegay M, Rockstroh JK, Machala L, Tomazic J, Girard PM, Januskevica I, Gronborg-Laut K, Lundgren JD, Cozzi-Lepri A for EuroSIDA in EuroCoord. HIV resistance testing and detected drug resistance in Europe. AIDS. 2015;29:1379-89. [PubMed]
  10. Ahn JV, Bailey H, Malyuta R, Volokha A, Thorne C for Ukraine Cohort of HIV-infected Childbearing Women in EuroCoord. Factors Associated with Non-disclosure of HIV Status in a Cohort of Childbearing HIV-Positive Women in Ukraine. AIDS Behav. 2015. [Epub ahead of print]
  11. Bagkeris E, Malyuta R, Volokha A, Cortina-Borja M, Bailey H, Townsend C, Thorne C for the Ukraine European Collaborative Study in EuroCoord. Pregnancy outcomes in an observational cohort study of HIV-positive women in Ukraine, 2000-2012. Lancet HIV. 2015. In press.
  12. Turkova A, Giacomet V, Goetghebuer T, Miloenko M, Nicolini LA, Noguera-Julian A, Rojo P, Volokha A, Indolfi G, Giaquinto C, Thorne C for the European Paediatric HIV/HCV Co-infection Study Group in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) in EuroCoord. HCV treatment in children and young adults with HIV/HCV co-infection in Europe. Journal of Viral Eradication. 2015. In press.
  13. Simmons R, Malyuta R, Chentsova N, Medoeva A, Kruglov Y, Yurchenko A, Copas A, Porter K, for the CASCADE Collaboration in EuroCoord. HIV Testing and Diagnosis Rates in Kiev, Ukraine: April 2013 - March 2014. PLoS One. 2015;10:e0137062. [Article
  14. Rosiñska M, Simmon R, Marzec-Bogusławska A, Janiec J, Porter K. Relating HIV testing patterns in Poland to risky and protective behaviour. AIDS Care 2015;11:1-9. [Article
  15. Pantazis N, Touloumi G, Meyer L, Olson A, Cotagliola D, Kelleher AD, Lutsar I, Chaix M-L, Fisher M, Moreno S, Porter K for CASCADE Collaboration in EuroCoord. The impact of transient cART in early HIV infection on viral suppression and immunologic response in later treatment. AIDS 2015. In press.
  16. The Migrants Working Group on behalf of COHERE in EuroCoord. Monge S, Jarrín I, Mocroft A, Sabin CA, Touloumi G, van Sighem A, Abgrall S, Dray-Spira R, Spire B, Castagna A, Mussini C, Zangerle R, Hessamfar M, Anderson J, Hamouda O, Ehren K, Obel N, Kirk O, de Monteynard LA, Antinori A, Girardi E, Saracino A, Calmy A, De Wit S, Wittkop L, Bucher HC, Montoliu A, Raben D, Prins M, Meyer L, Chene G, Burns F, Del Amo J. Mortality in migrants living with HIV in Western Europe (1997-2013): a collaborative cohort study. Lancet HIV. 2015;2:e540-549. [PubMed]
  17. Hepatitis C-working group for Cohere in EuroCoord: Smit C, Arends J, Peters L, Montforte Ad, Dabis F, Zangerle R, Daikos G, Mussini C, Mallolas J, de Wit S, Zinkernagel A, Cosin J, Chene G, Raben D, Rockstroh J. Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in EuroCoord. BMC Infectious Diseases. 2015;15:498. [Article]
  18. Late presenters working group in COHERE in EuroCoord. Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Euro Surveill. 2015. [Epub ahead of print
  19. Antiretroviral Therapy Cohort Collaboration (ART-CC), Canadian Observational Cohort Collaboration (CANOC), The UK Collaborative HIV Cohort Study (UK CHIC), the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. AIDS. 2015. [Epub ahead of print]

Conference abstracts

  1. Gibb D. Preventing Pediatric HIV and Managing HIV-Infected Children: Where Are We Now, and Where Are We Going? Plenary speaker, 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Webcast]
  2. Jarrin I, Dalmau J, Pantazis N, Olson A, Mussini C, Phillips A, Boufassa F, Costagliola, Porter K, Blanco J, del Amo J, Marinez-Picado J. Rapid progression hinders the recovery of CD4+ T Cells following initiation of cART. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Poster]
  3. Mangal TD. Joint Estimation of HIV Progression and Mortality Among HIV Seroconverters including the CASCADE Collaboration in EuroCoord. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Webcast]
  4. Simmons R, Malyuta R, Chentsova C, Karnets I, Murphy G, Duong Y, Dobbs T, Medoeva A, Kruglov Y, Yurchenko A, Copas A, Porter K. HIV incidence estimates, introducing the Limiting Antigen Avidity EIA to existing HIV surveillance in Kiev City, Urkaine: 2013-2014. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Poster]
  5. Olson A, Sabin C, Prins M, Meyer L, del Amo J, Chene G, Hamouda O, Touloumi G, Porter K. Is survival following HIV seroconversion still improving, 17 years after the introduction of cART? 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Poster]
  6. Olson A, Kucherer C, Sonnerborg A, de Mendoza C, Zangerle R, Prins M, Gill J, Bakken Kran AM, Paraskevis D, Porter K. Temporal trends of transmitted HIV drug resistance following seroconversion. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Poster]
  7. Thiebaut R on behalf of the Standard Reference Distribution of CD4 Working Group of COHERE in EuroCoord. Reference curves for CD4 response to antiretroviral treatment in HIV-1 infected naive patients. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Poster]
  8. Butler K, on behalf of the BREATHER Trial Team. ART with Weekends Off is Noninferior to Continuous ART in Young People on EFV + 2NRTI. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Webcast]
  9. Freguja R, Poulson H, Del Bianco P, Compagnucci A, Saidi Y, Giaquinto C, Harper L, Gibb D, Klein N, De Rossi A. Long-Term Consequences of Planned Treatment Interruption in HIV-1 Infected Children. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Poster].
  10. Ingle S, Miro JM, Furrer H, Justice A, Saag M, Manzardo C, Esteve A, Sterne J, May M, on behalf of COHERE in EuroCoord, CNICS and NA-ACCORD. Impact of ART on Mortality in Cryptococcal Meningitis Patients: High-Income Settings. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Poster]
  11. Bucher H on behalf of COHERE in EuroCoord. Chronic Hepatitis B and C Infection and Risk for Non-Hodgkin Lymphoma in HIV Infected Patients. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Poster]
  12. Panayidou K, Kirk O, on behalf of the IeDEA and COHERE in EuroCoord Collaborations.Immunodeficiency at the start of ART: A global view. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Poster]
  13. Panayidou K, Judd A, on behalf of the IeDEA and COHERE in EuroCoord.Immunodeficiency at the start of ART in children: A global view. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Poster]
  14. Grint D, Peters L, Rockstroh J, Lacombe K, Horban A, Khromova I, Gatell J, d'Arminio Monforte A, Lundgren JD, Mocroft A, on behalf of EuroSIDA in EuroCoord. A Prognostic Score Estimating the Risk of Liver-Related Death Among HIV/HCV Coinfected Subjects. 22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Abstract]
  15. Laut, K, Shepherd LC, Pedersen C, Rockstroh J, Sambatakou H, Paduta D, Lundgren J, Mocroft A, Kirk O, on behalf of EuroSIDA in EuroCoord. New Marker of Standard-of-ART Care: Percentage of Time on cART With Suppressed HIV-RNA.22nd Conference on Retroviruses and Opportunistic Infections, 23-26 February 2015, Seattle, US. [Poster]

2014

Publications

  1. Judd A, Duong T, Galli L, Goetghebuer T, Ene L, Noguera A, Ramos Amador JT, Pimenta JM, Thorne C, Giaquinto C on behalf of the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Post-licensing safety of fosamprenavir in HIV-infected children in Europe. Pharmacoepidemiology and Drug Safety. 2014;23:321-5. [PubMed]
  2. Mocroft A, Ryom L, Reiss P, Furrer H, D'Arminio Monforte A, Gatell J, de Wit S, Beniowski M, Lundgren J, Kirk O; for EuroSIDA in EuroCoord. A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection. HIV Med. 2014;15:144-52. [Article]
  3. Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, Monforte AD, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N; The Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Research Europe (COHERE) in EuroCoord. Long-term mortality in HIV positive individuals virally suppressed for more than three years with incomplete CD4 recovery. Clin Infect Dis. 2014;58:1312-21. [PubMed]
  4. Grint D, Peters L, Rockstroh J, de Wit S, Mitsura VM, Knysz B, Pedersen C, Kirk O, Lundgren JD, Mocroft A for EuroSIDA in EuroCoord.  Increased incidence of antiretroviral drug discontinuation among patients with viremic HCV coinfection and high hyaluronic acid, a marker of liver fibrosis. AIDS 2014;28:577-8. [PubMed]
  5. Mocroft A, Ryom L, Begovac J, D’Arminio Monforte A, Vassilenko A, Gatell J et al  for EuroSIDA in EuroCoord. Deteriorating renal function and clinical outcomes in HIV-positive persons. AIDS 2014;28:727-37[PubMed
  6. Zoufaly A, Cozzi-Lepri A, Reekie J, Kirk O, Lundgren JD, Reiss P, Jevtovic D, Machala L, Zangerle R, Mocroft A, Lunzen JV, for EuroSIDA in EuroCoord.  Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. PLoS One 2014;9:e87160. doi: 10.1371/journal.pone.0087160[Article
  7. The Natural History Project Writing Group for Collaboration of Observational HIV Epidemiological Research In Europe (COHERE) in EuroCoord: Nakagawa F, Lodwick R, Smith C, Costagliola D, van Sighem A, Ledergerber B, d’Arminio Monforte A, Dorrucci M, Torti C, Suarez-Lozano I, Obel N, Brockmeyer N, Thiebaut R, Lundgren J, Castagna A, Alejos B, De Wit S, Zangerle R, Pantazis N, Ehren K, Casabona J, Grarup J, Chêne G, Phillips A. Factors associated with short-term changes in HIV viral load and CD4 cell count in antiretroviral-naïve individuals. AIDS 2014;28:1351-56. [Article
  8. Olson A, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS and Porter K for CASCADE Collaboration in EuroCoord An Evaluation of HIV Elite Controller Definitions within a Large Seroconverter Cohort Collaboration. PLOS ONE 2014;9:e86719. doi: 10.1371/journal.pone.0086719 [Article]
  9. Bailey H, Townsend CL, Cortina-Borja M, Thorne C, for the European Collborative Study in EuroCoord. Adherence to antiretroviral therapy during pregnancy and the first year postpartum among HIV-positive women in Ukraine. J Acquir immune Defic Syndr. 2013;64:58-65. [Article]
  10. Simmons R, Semenenko I, Tolpina M, Tereschenko R, Kotlik L, Zasyptka L, Murphy G, McKinney E, Copas A, Malyuta R, Porter K; CASCADE collaboration in EuroCoord. High percentage of recent HIV infection leading to onward transmission in Odessa, Ukraine associated with young adults. AIDS and Behavior 2014;18:411-418. [PubMed]
  11. Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, Ghosn J, Dorrucci M, Johnson A, Sannes M, Moreno S, Porter K; for CASCADE Collaboration in EuroCoord. Evaluation of rapid progressors in HIV infection as an extreme phenotype. J Acquir Immune Defic Syndr. 2014;67:15-21. [Article]
  12. Van der Helm J, Jansen I, Porter K, Geskus R, Lodi S, Meyer L, Sabin C, Schuitemaker H, Bartmeyer B, d'Arminio Monforte A, Prins M for CASCADE Collaboration in EuroCoord.The characterization of long-term non-progression of HIV-1 infection. TheLancet HIV 2014;1:e41-e48. doi: 10.1016/S2352-3018(14)70016-5. [Abstract]
  13. Pantazis N, Porter K, Costagliola D, De Luca A, Ghosn J, Guiguet M, Johnson A, Kelleher A, Morrison C, Thiebaut R, Wittkop L, Touloumi G, for the CASCADE Collaboration in EuroCoord. Temporal trends in prognostic markers of HIV-1 virulence and transmissibility. An observational cohort study. Lancet HIV 2014. doi:10.1016/S2352-3018(14)00002-2 [Abstract] [Article] and [Supplementary Appendix]
  14. Shepherd L, Souberbielle JC, Bastard JP, Fellahi S, Capeau J, Reekie J, Reiss P, Blaxhult A, Bickel M, Leen C, Kirk O, Lundgren JD, Mocroft A, Viard JP on behalf of EuroSIDA in EuroCOORD. Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. J Infect Dis. 2014;210:234-43. [PubMed]
  15. Mocroft A, Reiss P, Rakhmanova A, Banhegyi D, Phillips AN, de Wit S, Ristola M, Lundgren JD, Grarup J, Kirk O; EuroSIDA in EuroCOORD. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. Infection. 2014;42:757-62. [Article]
  16. Peters L, Mocroft A, Soriano V, Rockstroh J, Kirkby N, Reiss P, Katlama C, Zakharova N, Flisiak R, Lundgren J; EuroSIDA in EuroCoord. High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance. HIV Med. 2014;15:615-20. [PubMed]
  17. The Socio-economic Inequalities and HIV Writing Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord. AIDS. 2014;28:2297-306. doi: 10.1097/QAD.0000000000000410 [PubMed]
  18. Laut K, Mocroft A, Lazarus JV, Reiss P, Rockstroh J, Karpov I, Rakhmanova A, Knysz B, Moreno S, Gargalianos P, Lundgren JD, Kirk O, for EuroSIDA in EuroCoord. Regional differences in self-reported HIV care and Management in the EuroSIDA study. J Int AIDS Soc. 2014;17:19504. [Article]
  19. Borges AH, Lundgren JD, Ridolfo A, Katlama C, Antunes F, Grzeszczuk A, Blaxhult A, Mitsura VM, Doroana M, Battegay M, Gargalianos P, Mocroft A, EuroSIDA in EuroCoord. Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. AIDS. 2014;28:2565-2571. [PubMed]
  20. Llibre JM, Cozzi-Lepri A, La Rosa JA, Pedersen C, Ristola M, Losso M, Mocroft A, Mitsura VM, Ormaasen V, Maltez F, Beniowski M, Paredes R, EuroSIDA in EuroCoord. Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression. J Int AIDS Soc. 2014;17:19810. [Article]
  21. Schultze A, Paredes R, Sabin C, Phillips AN, Pillay D, Kirk O, Lundgren JD, Pozniak A, NElson M, Cozzi-Lepri A, EuroSIDA in EuroCoord. Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure. J Int AIDS Soc. 2014;17:19737. [Article]
  22. Shepherd L, Borges AH, Ravn L, Harvey R, Jean-Paul V, Bower M, Grulich A, Silverberg M, De Wit S, Kirk O, Lundgren J, Mocroft A, EuroSIDA in EuroCoord. Predictive value of prostrate-specific antigen for prostate cancer: a nested case-control study in EuroSIDA. J In AIDS Soc. 2014;17:19510. [Article
  23. Peters L, Mocroft A, Lundgren J, Grint D, Kirk O, Rockstroh JK. HIV and hapatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspecive. BMC Infect Dis. 2014;14:S13. [Article]
  24. Ingle SM, May M, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, Fatkenheuer G, Reiss P, Saag MS, Manzardo C, Grabar S, Bruyand M, Moore D, Mocroft A, Sterling TR, D'Arminio Monforte A, Hernando V, Teira R, Guest J, Cavassini M, Crane HM, Sterne JA, Antiretroviral Therapy Cohort Collaboration. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis. 2014;59:287-97. [Article]
  25. Boufassa, F, Lechenadec J, Meyer L, Costagliola D, Hunt PW, Pereyra F, Deeks S, Pancino G, Taulera O, Lichterfeld M, Delobel P, Saez-Cirion A, Lambotte O. Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration. PLoS One. 2014;9:e85516. [Article]
  26. Bastiaans DE, Forcat S, Lyall H, Cressey TR, Hansudewechakul R, Kanjanavanit S, Noquera-Julian A, Konigs C, Inshaw JR, Chalermpantmetaqul S, Saidi Y, Compagnucci A, Harper LM, Giaquinto C, Colbers AP, Burger DM. Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands. Pediatr Infect Dis J. 2014;33:301-305. [PubMed]
  27. Yin DE, Warshaw MG, Miller WC, Castro H, Fiscus SA, Harper LM, Harrison LJ, Klein NJ, Lewis J, Melvin AJ, Tudor-Williams G, McKinney RE Jr. Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation. Pediatrics. 2014;134:e1104-1116. [PubMed]

Conference abstracts

  1. Pantazis N, Porter K, Costagliola D, De Luca A, Ghosn J, Guiguet M, Kelleher A D, Morrison C, Thiebaut R, Touloumi G, on behalf of the CASCADE Collaboration in EuroCoord. Temporal trends in prognostic markers of HIV-1 virulence and transmissibility. Presented at the 21st Conference on Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston, US. [Webcast]
  2. Lyall H on behalf of PENTA. Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands (PENTA 18/KONCERT). Presented at the 21st Conference on Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston, US.  [Webcast]
  3. An der Heiden M, Zoufaly A, Sabin C, van Lunzen J, Stellbrink H, Gunsenheimer-Bartmeyer B, Vanhems P, Perez-Hoyos S, Chene G, Hamouda O, on behalf of CASCADE Collaboration in EuroCoord. The clinical impact of viral load copy years in antiretroviral-naïve HIV seroconverters. Presented at the 21st Conference on Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston, US. [Abstract 291]
  4. Olson A, Walker S, Suthar A, Sabin C, Bucher H, Jarrin I, Moreno S, Perez-Hoyos S, Porter K, Ford D, CASCADE Collaboration in EuroCoord. Value of viremia copy years in deciding optimal timing of ART initiation in adults with HIV. Presented at the 21st Conference on Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston, US. [Abstract 558]
  5. Wyss N, Egger M, Bohlius J, on behalf of the Malignancy Working Group for COHERE in EuroCoord. Kaposi Sarcoma in the era of combination antiretroviral therapy. Presented at the 21st Conference on Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston, US. [Abstract 711]
  6. De Luca A, Flandre P, Castagna A, Ceccherini-Silberstein F, Cozzi-Lepri A, Churchill D, de Wit S, Dunn D, Fuchs W, Garcia F, Gunthard, A Imaz, T Kordossis, C Mussini, N Obel, B Roca, MM Santoro, E Schuelter, C Torti, A van Sighem, AM Wensing, L Wittkop H, Zangerle R, Zazzi M, Descamps D, CHAIN and COHERE in EuroCoord. Improved weighted darunavir genotypic mutation score predicting treatment response for HIV-1 subtype B and non-B infected patients receiving darunavir in a salvage regimen. Presented at the International Workshop on Antiviral Drug Resistance: Meeting the Global Challenge, 3-7 June 2014, Berlin, Germany. [Abstract 99]
  7. Mocroft A, Lundgren J, Kirk O, for the Late Presentation Work Group of COHERE. Continued late presentation for HIV care across Europe. Presented at the HepHIV 2014 Conference: HIV and Viral Hepatitis: Challenges of Timely Testing and Care, 5-7 October 2014, Barcelona, Spain. [Webcast]
  8. Fidler S, Olson A, Fox J, Phillips A, Morrison C, Thornhill J, Bucher H, Muga R, Porter K. The importance of viral blips and duration of therapy initiated in primary infection in maintaining viral control after stopping cART. Presented at the 2014 HIV Drug Therapy Glasgow Meeting, 2-6 November 2014, Glasgow, Scotland. Poster #P288.  [Abstract
  9. Aebi-Popp K, Bailey H, Malyuta R, Volokha A, Thorne C for the Ukraine European Collaborative Study in EuroCoord. High prevalence of HSV-2 co-infection among HIV-positive women in Ukraine, but no increased HIV mother-to-child transmission risk. Presented at 32nd Annual Meeting of the European Society for Paediatric Infectious Diseases, 6-10 May 2014, Dublin, Ireland.
  10. Thorne C for the European Paediatric HIV/HCV Co-Infection Study Group in the European Pregnancy and Paediatric HIV Cohort Collaboration in EuroCoord. HIV/HCV co-infection in children and young people in Europe: results from a cohort collaboration. 32nd Annual Meeting of the European Society for Paediatric Infectious Diseases. 6-10 May 2014, Dublin, Ireland.
  11. Shepherd L, Borges AH, Ravn L, Harvey R, Viard J-P, Bower M, Grulich A, Silverberg M, De Wit S, Kirk O, Lundgren J, Mocroft A on behalf of EuroSIDA in EuroCoord. Predictive value of Prostate Specific Antigen (PSA) for prostate cancer (PCa): A nested case control study in EuroSIDA.. Presented at HIV Drug Therapy Glasgow 2014, 2-6 November 2014, Glasgow, Scotland. [Poster] [Webcast]
  12. Laut K, Mocroft A, Lazarus JV, Reiss P, Rockstroh J, Karpov I, Rakhmanova A, Knysz B, Moreno S, Gargalianos P, Lundgren JD, Kirk O, for EuroSIDA in EuroCoord. Regional differences in self-reported HIV care and Management in the EuroSIDA study. Presented at HIV Drug Therapy Glasgow 2014, 2-6 November 2014, Glasgow, Scotland. [Poster] [Webcast]
  13. Schultze A, Paredes R, Sabin C, Phillips AN, Pillay D, Kirk O, Pozniak A, Nelson M, Lundgren J, Cozzi-Lepri A on behalf of EuroSIDA in EuroCoord, UK CHIC and UK HDRD. Detection of Resistance Mutations and CD4 Slopes in Individuals Experiencing Sustained Virological Failure. Presented at HIV Drug Therapy Glasgow 2014, 2-6 November 2014, Glasgow, Scotland. [Poster] [Webcast]
  14. Mocroft A, Ryom L, Lapadula G, Reiss P, Blaxhult A, Furrer HJ, Kutsyna G, Gatell J, Begovac J, Domingo P, Kirk O, Lundgren JD for EuroSIDA in EuroCoord. The prevalence and predictive value of dipstick urine protein (DUP) in HIV-positive persons in Europe. Presented at HIV Drug Therapy Glasgow 2014, 2-6 November 2014, Glasgow, Scotland. [Poster]
  15. Casadellà Fontdevila M, Cozzi-Lepri A, Phillips A, Noguera Julian M, Bickel M, Sedlacek D, Kronborg G, Lazzarin A, Zilmer K, Clotet B, Lundgren JD, Paredes R, for EuroSIDA in EuroCoord. Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death. Presented at HIV Drug Therapy Glasgow 2014, 2-6 November 2014, Glasgow, Scotland. [Poster]
  16. Llibre JM, Cozzi-Lepri A, Valencia La Rosa J, Pedersen C, Ristola M, Losso M, Mocroft A, Mitsura VM, Ormaasen V, Maltez F, Beniowski M, Paredes R, on behalf of EuroSIDA in EuroCoord. Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression. Presented at HIV Drug Therapy Glasgow 2014, 2-6 November 2014, Glasgow, Scotland. [Poster]
  17. Lazarus J, Peters L, Gronborg Laut K, Lundgren JD, Kirk O, Mocroft A on behalf of the EuroSIDA study in EuroCoord. Regional Differences in hepatitis testing, vaccination and treatments in the EuroSIDA study. HepHIV 2014 Conference, 5-7 October 2014, Barcelona, Spain. [Poster]
  18. Grint D, Peters L, Rakmanova A, Rockstroh JK, Karpov I, Galli M, Domingo P, Kirk O, Lundgren JD, Mocroft A for EuroSIDA in EuroCoord. Liver-related death among HIV/HCV coinfected individuals, implications for the era of directly acting antivirals. 21st Conference on Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston, US. [Abstract 652]
  19. Fakoya I, Alvarez-del Arco D, Monge S, Gennotte A, Volny-Anne A, Wengenroth C, Touloumi G, Prins M, Barros H, Staehelin C, del Amo J, Burns F, for EuroCoord. aMASE (advancing migrant access to health services in Europe): study design and methods. EUPHA's 5th European Conference on Migrant and Ethnic Minority Health, 10-12 April, Granada, Spain. Poster 237.
  20. Efsen AMW, Schultze A, Post FA, Panteleev A, Furrer H, Miller R, Losso MH, Toibaro J, Skrahin A, Miro JM, Cayla JA, Girardi E, Bruyand M, Obel N, Podlekareva DN, Lundgren JD, Mocroft A, Kirk O for the TB:HIV study group in EuroCoord. Major challenges in clinical management of TB/HIV coinfected patients in Eastern Europe compared with Western Europe and Latin America. HIV Drug Therapy Glasgow 2014, 2-6 November 2014, Glasgow, Scotland. [Webcast]
  21. Bastiaans D on behalf of PENTA: Parmacokinetics of lopinavir/ritonavir once daily compared to twice daily in virologically supressed, treament-experienced, HIV infected children. 32nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), 6-10 May, Dublin, Ireland. [Slides]
  22. Bagkeris E, Malyuta R, Volokha A, Corina Borja M, Bailey H, Townsend C, Thorne C for the ukraine European Collaborative Study in EuroCoord. Social deprivation and preterm delivery in HIV-positive childbearing women in Ukraine. Economic and Social Research Frontiers in Population Health 2014 conference, 11 July, London, UK.
  23. Turkova, A for the European Paediatric HIV/HCV co-infection Study group in EPPICC in EuroCoord. Outcomes of HCV treatement in children with HIV/HCV co-infection in Europe. 6th International Workshop on HIV Pediatrics, 18-19 July, Melbourne, Australia.
  24. Turkova, A for teh European Paediatric HIV/HCV Co-infection Study group in EPPICC in EuroCoord. Uptake and outcomes of HCV treatment in children and young adults with HIV/HCV co-infection in Europe. 20th International AIDS Conference, 20-25 July, Melbourne, Australia. [Poster]

2013

Publications

  1. Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Vanhems P, Boufassa F, Guiguet M, Porter Kholoud, for CASCADE Collaboration in EuroCoord. Symptomatic Illness and Low CD4 Cell Count at HIV Seroconversion as Markers of Severe Primary HIV Infection.PLoS ONE 2013;8(11):e78642. [Article]
  2. Van der Helm J, Geskus R, Sabin C, Meyer L, del Amo J, Chêne G, Dorrucci M, Muga R, Porter K, Prins M on behalf of CASCADE collaboration in EuroCoord. Effect of HCV infection on cause-specific mortality following HIV seroconversion before and after 1997. Gastroenterology 2013;144:751-760. [Article]
  3. Aebi-Popp K, Mulcahy F, Glass TR, Rudin C, Martinez de Tejada B, Bertisch B, Fehr J, Grawe C, Scheibner K, Rickenbach M, Hoesli I, Thorne C; for the European Collaborative Study in EuroCoord and the Swiss Mother & Child HIV Cohort Study. Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery. J Acquir Immune Defic Syndr. 2013;64:58-65 [PubMed]
  4. Mocroft A, Lundgren JD, Sabin ML, Monforte Ad, Brockmeyer N, Casabona J, Castagna A, Costagliola D, Dabis F, De Wit S, Fätkenheuer G, Furrer H, Johnson AM, Lazanas MK, Leport C, Moreno S, Obel N, Post FA, Reekie J, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Lozano I, Torti C, Warszawski J, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Kirk O; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord. Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med. 2013;10:e1001510. [Article]
  5. Bailey H, Townsend CL, Cortina-Borja M, Thorne C; for the European Collaborative Study in EuroCoord. Improvements in virological control among women conceiving on cART in Western Europe. AIDS. 2013;27:2312-5. [PubMed]
  6. Smoleń-Dzirba J, Rosińska M, Kruszyński P, Bratosiewicz-Wąsik J, Janiec J, Beniowski M, Bociąga-Jasik M, Jabłonowska E, Szetela B, Wąsik TJ. Transmission of drug-resistant HIV-1 variants among individuals with recent infection in southern Poland. Curr HIV Res. 2013 Jun;11:288-94. [PubMed]
  7. Rockstroh J, Peters L, Grint D, Soriano V, Reiss P, d’Arminio Monforte A, Beniowski M, Losso M, Kirk O, Kupfer B, Mocroft A, for EuroSIDA in EuroCoord. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? J. Hepatology 2013; 59:213-220. [Article]
  8. Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O and Mocroft A for EuroSIDA in EuroCoord. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Medicine 2013 [Article].
  9. Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D, Castagna A, d'Arminio Monforte A, Gazzard B, Gutierrez F, Hurtado I, Jansen K, Meyer L, Muñoz P, Obel N, Soler-Palacin P, Papadopoulos A, Raffi F, Ramos JT, Rockstroh JK, Salmon D, Torti C, Warszawski J, de Wit S, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Lundgren JD; Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord. The incidence of AIDS defining illnesses at a current CD4 count > 200/mm3 in the post combination antiretroviral therapy era. CID 2013; 57:1038-47 [Article]
  10. AM Werlinrud Efsen, A Panteleev, D Grint, DN Podlekareva, A Vassilenko, A Rakhmanova, I Zeltina, MH Losso, R Miller, E Girardi, J Caylá, F Post, JM Miro, M Bruyand, H Furrer, N Obel, JD Lundgren, A Mocroft, O Kirk. The TB:HIV study in EuroCoord. TB meningitis in HIV-positive patients in Europe and Argentina - Clinical outcome and factors associated with mortality. BioMed Research International.; Volume 2013, Article ID 373601. [Article]
  11. Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM; Beijing PRIMO cohort study; CASCADE Collaboration in EuroCoord. Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. J Acquir Immune Defic Syndr. 2013 Apr 1;62:441-6. [PubMed]
  12. Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d’Arminio Monforte A, Amornkul P, Bartmeyer B, Sannes M, Venet A, Lambotte O and Meyer L on behalf of the CASCADE Collaboration in Eurocoord. Natural History of HIV control since seroconversion Experience from the CASCADE collaboration. AIDS. 2013 Sep 24;27(15):2451-60. [PubMed]
  13. Simmons R, Semeneko I, Tolpina M, Tereschenko R, Kotlik L, Zasyptka L, Murphy G, McKinney E, Copas A, Malyuta R, Porter K. High percentage of recent HIV infection leading to onward transmission in Odessa, Ukraine associated with young adults. AIDS Behav 2013. [Epub ahead of print]
  14. Pantazis N, Kenward MG, Touloumi G on behalf of CASCADE Collaboration in EuroCoord. Performance of parametric survival models under non-random interval censoring: a simulation study. Computational Statistics and Data Analysis 2013;63,16-30. [Abstract]
  15. Touloumi G, Pantazis N, Chaix ML, Bucher HC, Zangerle R, Bakken Kran AM, Thiebaut R, Masquelier B, Kucherer C, d’Arminio Monforte A, Meyer L and Porter K for CASCADE Collaboration in EuroCoord. Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE Collaboration. PLoS ONE 2013; 8(7):e71174. [Article]
  16. Peters L, Mocroft A, Soriano V, Rockstroh J, Rauch A, Karlsson A, Knysz B, Pradier C, Zilmer K, Lundgren JD, for EuroSIDA in EuroCoord. Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-related Death in HIV/Viral Hepatitis Coinfected Patients. PLoS One 2013;27;8(5):e64283. [Article]
  17. Bailey H, Townsend C, Semenenko I, Malyuta R, Cortina-Borja M and Thorne C for the Ukraine European Collaborative Study Group in EuroCoord. Impact of expanded access to combination antiretroviral therapy in pregnancy: results from a cohort study in Ukraine. Bulletin of the World Health Organization 2013;91:491-500. [Article] 
  18. Rosińska M, Marzec-Boguslawska A, Janiec J, Smolen-Dzirba J, Wasik T, Gniewosz J, Zalewska M, Murphy G, McKinney E, Porter K for the CASCADE Collaboration in EuroCoord. High percentage of recent HIV infection among HIV-positive individuals newly-diagnosed at voluntary counselling and testing sites in Poland in 2006. AIDS Res Hum Retroviruses 2013;29:805-13. [Article]
  19. Ryom L, Kirk O, Lundgren J, Reiss P, Pedersen C, De Wit S, Buzunova S, Gasiorowski J, Gatell J, Mocroft A; EuroSIDA in EuroCoord. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. HIV Med 2013;14:503-8.[PubMed]
  20. Porter K, Lodi S, Meyer L. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion--reply. JAMA Intern Med. 2013 Mar 25;173:476-7. doi: 10.1001/jamainternmed.2013.2784. [PubMed]
  21. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants. AIDS 2013;27:991–1000. [PubMed]
  22. Bunupuradah T, Duong T, Compagnucci A, McMaster P, Bernardi S, Kanjanavanit S, Rampon O, Faye A, Saïdi Y, Riault Y, de Rossi A, Klein N, Ananworanich J, Gibb D; on behalf of the PENTA 11 Extension Study Group. Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions in the PENTA 11 Study. AIDS. 2013 Feb 20;27:579-89 [PubMed]
  23. Grint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B, Suetnov O, Lazzarin A, Ledergerber B, Rockstroh J, Mocroft A; EuroSIDA in EuroCoord. Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Med 2013;14(6):370-8. [Article]
  24. Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix ML, Bucher H, Kücherer C, Zangerle R, Bakken Kran AM, Porter K, on behalf of the CASCADE collaboration in EuroCoord. Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline and viral load set point in European seroconverter cohorts. CID 2013;56:888-97. [Article]
  25. The Pursuing Later Treatment Option II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group. Predictors of CD4 cell counts of HIV-1-infected persons after virologic failure to all three original antiretroviral drug classes. JID 2013;207:759-67. [Article]
  26. Harrison L, Ananworanich J, Hamadache D, Compagnucci A, Penazzato M, Bunupuradah T, Mazza A, Ramos JT, Flynn J, Rampon O, Mellado Pena MJ, Floret D, Marczynska M, Puga A, Forcat S, Riault Y, Lallemant M, Castro H, Gibb DM, Giaquinto C. On Behalf of the Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team. Adherence to Antiretroviral Therapy and Acceptability of Planned Treatment Interruptions in HIV-Infected Children. AIDS Behav 2013 Jan;17:193-202. [Article]
  27. Mocroft A, Phillips A, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Kirk O, Lundgren JD; for EuroSIDA in EuroCoord. CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. AIDS 2013;27:907-918.[Article]
  28. Lodi S, del Amo J, D’Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E, and theCASCADE collaboration in EuroCoord.Risk of tuberculosis following HIV seroconversion in low-burden tuberculosis countries. Thorax 2013;68:207-13. [PubMed]
  29. Søgaard OS, Reekie J, Ristola M, Jevtovic D, Karpov I, Beniowski M, Servitskiy S, Domingo P, Reiss P, Mocroft A, Kirk O. Severe bacterial non-aids infections in HIV-positive persons: incidence rates and risk factors. J Infect 2013;66:439-46. [Article]  

Conference abstracts

  1. Shepherd L et al. for EuroSIDA in EuroCoord. Infection related and unrelated malignancies, HIV and the aging population.  Presented at the 4th European AIDS Conference, 16-19 October 2013, Brussels, Belgium. [Presentation]
  2. A Mocroft et al. for EuroSIDA in EuroCoord. The spectrum of clinical disease and relationship with measures of deteriorating renal function. Presented at the 4th European AIDS Conference, 16-19 October 2013, Brussels, Belgium. [Presentation]
  3. A Schultze et al. for EuroSIDA in EuroCoord. Prevalence of detected drug resistance across different regions of Europe: Data from EuroSIDA 1997-2012. [Presentation]
  4. JP Viard et al. for EuroSIDA in EuroCoord. Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers in HIV-infected persons. Presented at the 4th European AIDS Conference, 16-19 October 2013, Brussels, Belgium. [Presentation
  5. AH Borges et al. for EuroSIDA in EuroCoord. Development of thrombocytopenia and risk of AIDS and serious non-AIDS events in Europe. Presented at the 4th European AIDS Conference, 16-19 October 2013, Brussels, Belgium. [Poster]
  6. A Cozzi-Lepri et al. for EuroSIDA in EuroCoord. Estimation of percentage of HIV-infected people with limited future drug options in a closed observational setting over the period 2007-2011 and beyond. [Poster]
  7. D Grint et al. for EuroSIDA in EuroCoord. Is Stavudine (D4T) still being used in EuroSIDA despite its association with toxicity and a higher frequency of sever adverse events. Presented at the 4th European AIDS Conference, 16-19 October 2013, Brussels, Belgium. [Poster]
  8. J-P Viard, et al. for EuroSIDA in EuroCoord. Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons: results from the EuroSIDA cohort study. Presented at the 4th European AIDS Conference, 16-19 October 2013, Brussels, Belgium. [Poster]
  9. Kirk et al. for EuroSIDA in EuroCoord. A survey of ATRIPLA use in clinical practice among treatment-naïve HIV-positive patients in Europe. Presented at the 4th European AIDS Conference, 16-19 October 2013, Brussels, Belgium. [Poster]
  10. M. Mansfeld, A. Skrahina, A.M. Panteleev, J.M. Miro, I. Zeltina, S. Tetradov, A. Mocroft, A.Grzeszczuk, L. Shepherd, N. Bolokadze, J.D. Lundgren, A. Matteelli, F.A. Post, O. Kirk, D.N. Podlekareva. The TB:HIV study in EuroCoord. Organisation and delivery of healthcare for HIV/TB coinfected patients in Europe. Presented at the 4th European AIDS Conference, 16-19 October 2013, Brussels, Belgium. [Presentation]
  11. J del Amo for the socio-economic inequalities working group of COHERE in EuroCoord. Response to combination antiretroviral treatment in HIV-positive individuals in Europe: variation by educational level. Presented at the 4th European AIDS Conference, 16-19 October 2013, Brussels, Belgium.
  12. S Monge on behalf of the migrants working group of COHERE in EuroCoord.  Mortality in migrants living with HIV in Western European countries: differences by geographical origin and gender. Presented at the 4th European AIDS Conference, 16-19 October 2013, Brussels, Belgium.
  13. C Marzolini on behalf of the obesity working group of COHERE in EuroCoord. Obese HIV-infected patients treated with efavirenz-containing regimens are at risk of virological failure. Presented at the 4th European AIDS Conference, 16-19 October 2013, Brussels, Belgium.
  14. H Bailey, R Malyuta, C Townsend, M Cortina Borja, C Thorne for the Ukraine European Collaborative Study in EuroCoord. Prevalence of and risk factors for perinatal depression in HIV-positive women in Ukraine. Presented at the 5th International HIV Pediatrics Workshop, 28-29 June 2013, Kuala Lumpur, Malaysia.
  15. H Bailey, C Townsend, I Semenenko, R Malyuta, M Cortina-Borja and C Thorne for the Ukraine European Collaborative Study in EuroCoord. Adherence to antiretroviral therapy in pregnancy and during the first year post-partum in HIV-positive women in Ukraine. Presented at the 7th IAS Conference on HIV pathogenesis treatment and prevention, 30 June – 3 July 2013, Kuala Lumpur, Malaysia. [Abstract]
  16. C Thorne, H Bailey, I Semenenko, R Tereschenko, I Adeyanova, E Kulakovskaya, L Ostrovskaya, R Malyuta. Missed opportunities for prevention of hepatitis B infection in childbearing women with HIV in Ukraine. Presented at the 7th IAS Conference on HIV pathogenesis treatment and prevention, 30 June – 3 July 2013, Kuala Lumpur, Malaysia. [Abstract]
  17. Fumiyo Nakagawa on behalf of the Stochastic Simulation of Outcomes of People with HIV in Europe (SSOPHIE) project working group in EuroCoord. Estimation of HIV-infected populations in Europe: a pilot study using data for men who have sex with men in the UK. 14th European AIDS Conference. 16th-19th October 2013. Brussels, Belgium. Poster Presentation #PE21/10.
  18. Lodi S on behalf of COHERE in EuroCoord. Late HIV diagnosis, late initiation of combination ART and mortality in Europe: variation by educational level. Presented at the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June– 3 July, Kuala Lumpur, Malaysia. [Abstract]
  19. Ngo-Giang-Huong N and Wittkop L on behalf of EuroCoord-CHAIN- EPPICC project team. Prevalence and impact of transmitted drug resistance (TDR) on response to ART in Children. Presented at the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June– 3 July, Kuala Lumpur, Malaysia. [Abstract]
  20. Casadellà M, Cozzi-Lepri A, Phillips A, Noguera-Julian M, Bickel M, Duiculescu D, Zilmer K, Clotet B, Lundgren JD, Paredes R for EuroSIDA in EuroCOORD. Detection of Non-R5 HIV-1 by Ultrasensitive Genotypic Testing Is Associated with CD4+ Count Decreases Also After the Initiation of ART. 11th European Meeting on HIV & Hepatitis, 20-22 March 2013, Rome, Italy.[Poster]
  21. Olson A, Touloumi G, Geskus R, Meyer L, Prins M, Chêne G, De Luca A, Costagliola D, and Porter K for CASCADE Collaboration in EuroCoord.Mean asymptomatic viral load, steady state viral load and CD4 cell count following acute infection as predictors of HIV disease progression.20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, US. [Abstract]
  22. Wittkop L on behalf of the EuroCoord-CHAIN subtype project team. Effect of HIV-1 subtypes on virological and immunological response to initial combination antiretroviral therapy (cART) – a European Multicohort Study. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, US. [Abstract]
  23. Mocroft A on behalf of the Opportunistic Infections project group of COHERE in EuroCoord. The incidence and risk of AIDS-defining illnesses (ADIs) at current CD4 counts of 500/mm3 or higher. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, US. [Abstract]
  24. Grint D, Peters L, Rockstroh J, Lundgren JD, de Wit S, Mitsura VM, Knysz B, Pedersen C, Kirk O, Mocroft A. Increased Risk Of Antiretriviral Drug Discontuniation among Patienst with High Hyaluronic Acid, a Marker of Liver Fibrosis. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, US. [Abstract]
  25. Mocroft A, Ryom L, Reiss P, Ledergerber B, Monforte A, Gatell J, de Wit S, Beniowski M, Lundgren JD and Kirk O for EuroSIDA in EuroCoord. A comparison of estimated glomerular filtration rates (eGFRs) using Cockcroft-Gault (CG) and the CKD-EPI estimating equations. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, US. [Abstract]
  26. Bailey H, Townsend CL, Cortina Borja M, Thorne C for the European Collaborative Study in EuroCoord. Trends and factors associated with virological failure among women conceiving on cART in Western Europe.  20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, US. [Abstract]
  27. Abei-Popp K, Mulcahy F, Glass T, Rudin C, Martinez de Tejada B, Bertisch B, Grawe C, Rickenbach M, Scheibner K, Hosli I and Thorne C for the European Collaborative Study in EuroCoord and teh Swiss Mother & Childre HIV Cohort Study. Vaginal delivery as an option for HIV-infected women: decreasing late preterm delivery rates in a European cohort collaboration. 5th International HIV Pediatrics Workshop, Kuala Lumpur, 28-29 June 2013. [Presentation]
  28. Turkova A, Thorne C, Galli L, Goetghebuer T, de Martino M, Oprea C, Ramos Amador JT, Giaquinto C for the European Pregnancy and Paediatric HIV Chohort Collaboration in EuroCoord. HCV treatment in children and young adults with HIV/HCV co-infections in Europe. 7th International AIDS Society Conference (IAS 2013), Kuala Lumpur, 30 June - 3 July 2013. [Abstract]

2012

Publications

  1. Van der Helm J, Geskus R, Sabin C, Meyer L, del Amo J, Chêne G, Dorrucci M, Muga R, Porter K, Prins M on behalf of CASCADE collaboration in EuroCoord. Effect of HCV infection on cause-specific mortality following HIV seroconversion before and after 1997. Gastroenterology 2013;144:751-760. [Article]
  2. Huang X, Lodi S , Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li A,  Xu X, Wu H and Johnson A, on behalf of the CASCADE collaboration in EuroCoord. Rate of CD4 decline and HIV-RNA change following HIV Seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. JAIDS 2012. [Article]
  3. Smoleń-Dzirba J, Rosińska M, Kruszyński P, Bratosiewicz-Wasik J, Janiec J, Beniowski M, Bociaga-Jasik M, Jablonowska E, Szetela B, Porter K, Wasik T, and the CASCADE collaboration in EuroCoord. Molecular epidemiology of recent HIV-1 infections in southern Poland. J Med Virol 2012;84:1857-68. [Article]
  4. Podlekareva DN, Reekie J,  Mocroft A, Losso M, Rakhmanova A, Bakowska E, Karpov IA, Lazarus J, Gatell J, Lundgren JD, Kirk O; EuroSIDA study in EuroCoord. Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. BMC Infect Dis 2012;12:229. [Article]
  5. Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O; for EuroSIDA in EuroCoord. HCV viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 2012;26:1917-1926. [PubMed]
  6. Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD; the EuroSIDA Study in EuroCOORD. The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression. Antivir Ther 2012;17:1291-300 [PubMed] 
  7. Hepatitis working group for COHERE in EuroCoord. Effect of hepatitis C treatment on CD4+ T-cell counts and the risk of death in HIV-hepatitis C co-infected patients. Antivir Ther 2012;17:1541-1550. [PubMed] 
  8. Zugna D, Geskus RB, de Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix M, Babiker A and Porter K for the CASCADE Collaboration in EuroCoord. Differences in time to virological failure, treatment change and interruption, between persons treated within 12 months of HIV seroconversion and in chronic infection. Antivir Ther 2012;17:1039-1048. [PubMed]
  9. Lodi S, Meyer L, Kelleher A, Rosińska M, Ghosn J, Sannes M, Porter K for the CASCADE Collaboration in EuroCoord. Immuno-virological control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012; 172:1252-5. [Article]
  10. Bakoyannis G, Touloumi G. Practical methods for competing risks data: A review. Stat Methods Med Res 2012; 21: 257-72.  [PubMed]
  11. Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O,  Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: The EuroSIDA Study. PLoS One 2012;7:e41673. [Article]
  12. de Wolf F, Sabin C, Kirk O, Thorne C, Chene G, Porter K for EuroCoord. Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience. Clin Invest 2012; 2: 255-264. [Article]
  13. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. All-cause mortality in treated HIV-infected adults with CD4 ≥500 /mm3 compared to the general population: evidence from a large European observational cohort collaboration. Int. J. Epidemiol. 2012; 41: 433-445. [Article]
  14. Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G on behalf of CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS One. 2012; 7: e32369. [Article]
  15. Alam N, Cortina-Borja M, Goetghebuer T, Marczynska M, Vigano A, Thorne C; European Paediatric HIV and Lipodystrophy Study Group in EuroCoord. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. J Acquir Immune Defic Syndr. 2012; 59: 314-24. [Article]
  16. The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. PLoS Med. 2012; 9: e1001194. [Article]
  17. Nakagawa F for the PLATO II group for COHERE in EuroCoord. Calendar time trends in the incidence and prevalence of triple-class viroligic failure in antiretroviral drug experienced people with HIV in Europe. J Acquir Immune Defic Syndr. 2012; 59: 294-9. [PubMed]
  18. The Pursuing Later Treatment Option II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis. 2012; 12: 119-27. [Article]
  19. Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, Monforte A, Phillips A, Lundgren J and Kirk O for the EuroSIDA study group. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS. 2012; 26: 315-323. [PubMed]
  20. Cozzi-Lepri A, Paredes R, Phillips AN, Clotet B, Kjær J, Von Wyl V, Kronborg G, Castagna A, Bogner JR and Lundgren JD for EuroSIDA in EuroCoord. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI.HIV Med. 2012; 13: 62-72. [PubMed]
  21. Jarrin I, Pantazis N, Gill MJ, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G, Johnson A, Hamouda O, García de Olalla P, Porter K, Del Amo J; CASCADE Collaboration in EuroCoord. Uptake of combination antiretroviral therapy (cART) and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis. 2012; 54: 111-8. [Article]
  22. Thorne C, Semenenko I, Malyuta R; for the Ukraine European Collaborative Study Group in EuroCoord. Prevention of mother-to-child transmission of HIV among pregnant women using injecting drugs in Ukraine, 2000-2010. Addiction 2012; 107: 118-28. [Article]

Conference abstracts

  1. Bastiaans DET et al on behalf of the PENTA 18 KONCERT Study Group. Pharmacokinetics of 100/25 mg lopinavir/ritonavir tablets in children when dosed twice daily according to FDA weight bands. 6th Netherlands Conference on HIV Pathogenesis, Prevention and Treatment, 27 November 2012, Amsterdam, Netherlands.
  2. Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jetovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O, Mocroft A for EuroSIDA in EuroCoord. Temporal Changes and Regional Differences in Treatment Uptake of Hepatitis C Therapy in EuroSIDA. 11th International Congress on Drug Therapy in HIV infection, 11-15 November 2012, Glasgow, UK. [Abstract]
  3. Mocroft M, Phillips A, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Kirk O, Lundgren J et al. for theEuroSIDA study in EuroCoord. CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. 11th International Congress on Drug Therapy in HIV infection, 11-15 November 2012, Glasgow, UK. [Abstract]
  4. Rockstroh JK, Grint D, Boesecke C, Soriano V, Lundgren JD, d'Arminio Monforte A, Mitsura VM, Kirk O, Mocroft A and Peters L for EuroSIDA in EuroCoord. Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected? 11th International Congress on Drug Therapy in HIV infection, 11-15 November 2012, Glasgow, UK. [Abstract]
  5. Ryom L, Kirk O, Lundgren JD, Reiss P, Pedersen C, De Wit S, Buzunova S, Gasiorowski J, Gatell JM and Mocroft A on behalf of EuroSIDA in EuroCoord. Advanced Chronic Kidney Disease, End-Stage Renal Disease and Renal Death in HIV-Positive Individuals in Europe. 11th International Congress on Drug Therapy in HIV infection, 11-15 November 2012, Glasgow, UK. [Abstract]
  6. Zoufaly A, Cozzi-Lepri A, Kirk O, Lundgren JD, Reiss P, Jetovic D, Machala L, Zangerle R, Mocroft A, van Lunzen J on behalf of EuroSIDA in EuroCoord. Immuno-virological discordance (ID) is associated with a higher frequency of fatal and non-fatal AIDS and non-AIDS. 11th International Congress on Drug Therapy in HIV infection, 11-15 November 2012, Glasgow, UK. [Abstract]
  7. Aebi-Popp K, Mulcahy F, Glass T, Rudin C, Martinez de Tejada B, Bertisch B, Grawe C, Rickenbach M, Scheibner K, Hösli I and Thorne C  for the European Collaborative Study in EuroCoord and the Swiss Mother & Child HIV Cohort Study. Pregnant women with HIV in Europe: How many achieve the aim of undetectable viral load at term and are able to deliver vaginally? 11th International Congress on Drug Therapy in HIV Infection, 11-15 November 2012, Glasgow, UK. [Abstract]
  8. Janiec J, Rosińska M, Smoleń-Dzirba J, Wąsik T, Beniowski M, Bociąga-Jasik M, Kalinowska-Nowak A, Jabłonowska E, Szetela B, Zalewska M, Porter K and the CASCADE collaboration in EuroCoord. What shapes the current HIV epidemic in southern Poland? Poster presentation 2012 European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE), 24-26 October 2012, Edinburgh, Scotland, UK.
  9. Pantazis N, Kenward M, Touloumi G on behalf of CASCADE Collaboration in EuroCoord. Performance of parametric survival models under non-random interval censoring: a simulation study. 33rd Conference of the International Society for Clinical Biostatistics, 19-23 August 2012, Bergen, Norway. Published in the 33rd Conference of the International Society for Clinical Biostatistics programme and abstract book, abstract P22.26, p.130. [Abstract]
  10. Bakoyannis G. Late entry bias in cohort studies with competing endpoints. 33rd Conference of the International Society for Clinical Biostatistics, 19-23 August 2012, Bergen, Norway. Published in the 33rd Conference of the International Society for Clinical Biostatistics programme and abstract book, abstract C26.4, p.66. [Abstract]
  11. Thorne C, Malyuta R, Semenenko I, Azhischeva E, Baryshnikova Y, Bashkatova N, Glutshenko E, Kaleeva N, Raus I, Soloha S, Ene L, Giaquinto C, Ukraine Paediatric HIV Cohort Study in EuroCoord. HIV disease progression markers and treatment of HIV-positive children in Ukraine. 19th International AIDS Conference, July 22-27 2012, Washington DC, USA. [Abstract]
  12. Smith R, Semenenko I, Tolpina M, Tereschenko R, Kotlik L, Zasyptka L, Murphy G, McKinney E, Malyuta R, Porter K on behalf of CASCADE Collaboration in EuroCoord. High percentage of recent HIV infection leading to onward transmission in Odessa, Ukraine associated with young adults. 19th International AIDS Conference, 22-27 July 2012, Washington DC, US. [Abstract]
  13. Lundgren J on behalf of the COHERE Late Presenters working group. Characteristics of individuals presenting late for care across Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). 19th International AIDS Conference, 22-27 July 2012, Washington DC, US. [Abstract]
  14. Bailey H, Malyuta R, Semenenko I, Townsend CL, Cortina Borja M and Thorne C for the Ukraine European Collaborative Study in EuroCoord. Receipt of cART among childbearing women in Ukraine: implications for vertical and horizontal transmission. Poster accepted for 4th International Workshop on HIV Pediatrics, 20-21 July 2012, Washington DC, USA.  
  15. Bastiaans D, Forcat S, Lyall H, Cressey T, Chalermpantmetagul S, Saïdi Y, Noguera Fortuny C, Compagnucci A, Bleier J, Giaquinto C, Colbers A, Burger D on behalf of PENTA KONCERT Study Group. Pharmacokinetics of 100/25 mg lopinavir/ritonavir tablets in children when dosed twice daily according to FDA weight bands. 4th International Workshop on HIV Pediatrics, 20-21 July 2012 Washington DC, US.
  16. Chiappini E, Ene L, Galli L, Giaquinto C, Goetghebuer T, Noguera AJ, Ramos JT, Rudin C, Tookey P, Thorne C (European Pregnancy and Paediatric HIV Cohort Collaboration in EuroCoord). Use of mono and combined neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in high risk situations in Europe.  4th International Workshop on HIV Pediatrics, Washington DC, USA, 20-21 July 2012.
  17. Van der Helm J on behalf of the CASCADE collaboration. Effect of hepatitis C coinfection on cause-specific mortality following HIV seroconversion in the pre-cART and cART eras. 47th annual meeting of the European Association for the Study of Liver (EASL), 18-22 April 2012,Barcelona, Spain.[Abstract]
  18. Judd A, Duong T, Ene L, Galli L, Goetghebuer T, Noguera-Julian A, Ramos J, Tookey P, Naver L, Thorne C and Giaquinto C on behalf of the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) in EuroCoord. Safety of fosamprenavir and darunavir in HIV-1 infected children in the European Union: ongoing post-marketing surveillance studies.  30th Annual meeting of the European Society for Paediatric Infectious Diseases, 8-12 May 2012, Thessaloniki, Greece. [Abstract]
  19. Olson A, Meyer L, Prins M, Thiebaut R, Guiguet M, Chaix M-L, Amornkul P, Babiker A and Porter K for CASCADE Collaboration in EuroCoord. Proportion of HIV elite controllers and loss of elite status according to two commonly used definitions. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US. [Abstract]
  20. Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Porter K for CASCADE Collaboration in EuroCoord. Identification of severe primary HIV infection through clinical, immunological and virological definitions. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US. [Abstract]
  21. Ramos J, Melvin D, Medin G, Compagnucci A, Bleier J, Boscolo V, Barclay L, Ory S, Giaquinto C, Gibb D. on behalf of the PENTA Steering Committee. Neurocognitive and Quality of Life Outcomes in Children after Planned Treatment Interruptions: the randomized PENTA 11 trial. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US.[Abstract]

2011

Publications

  1. The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Judd A, Penazzato M, Townsend C, Duong T, Castro H, Goetghebuer T, Warszawski J, Galli L, Chiappini E, de Martino M, Ene L, Giaquinto C, Königs C, LeChenadec J, Lyall H, Noguera Julian A, Ramos JT, Rojo-Conejo P, Rudin C, Thorne C, Tookey P, Tudor-Williams G, Gibb DM). Early antiretroviral therapy in HIV-1 infected infants in Europe, 1996-2008: treatment response and duration of first line regimens. AIDS 2011; 25: 2279-2287. [Article]
  2. Reekie J, Gatell J, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P, Kowalska J, Mocroft A, for the EuroSIDA in EuroCoord. Fatal and non-fatal AIDS and non-AIDS events in HIV-1 positive individuals with high CD4 counts according to viral load strata. AIDS. 2011; 25: 2259-68. [PubMed]
  3. Cozzi-Lepri A, Prosperi MCF, Kjær J, Dunn D, Paredes R, Sabin CA, Lundgren JD, Phillips AN, Pillay D, for the EuroSIDA and the United Kingdom CHIC/United Kingdom HDRD Studies. Can Linear Regression Modeling Help Clinicians in the Interpretation of Genotypic Resistance Data? An Application to Derive a Lopinavir-Score. PLoS One. 2011; 6: e25665.[Article]
  4. Soriano V, Grint D, Monforte A, Horban A, Leen C, Poveda E, Antunes F, de Wit S, Lundgren J, Rockstroh J, Peters L. Hepatitis delta in HIV-infected individuals in Europe. AIDS. 2011; 25: 1987-92. [PubMed]
  5. Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, Pantazis N, del Amo J, Johnson A M, Babiker A, Porter K on behalf of the CASCADE Collaboration in EuroCoord. Time from HIV seroconversion to reaching CD4 thresholds <200, <350 and <500 cells/mm3; assessment of need following changes in treatment guidelines. Clin Infec Dis 2011; 53: 817-825. [Article]
  6. Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 2011; 171: 1560-9. [Article]
  7. Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez-Arias L, Martinez-Picado J, the EuroSIDA study group. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. J Infect Dis. 2011; 204: 741-52. [Article]
  8. Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O; EuroSIDA study group. Tuberculosis among HIV-postive patients across Europe: changes over time and risk factors. AIDS 2011; 25: 1505-1513. [PubMed]
  9. Jaffe H, De Stavola B, Carpenter L, Porter K and Cox D. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. AIDS 2011; 25: 1395-1403. [PubMed] 
  10. European Collaborative Study in EuroCoord, Bailey H, Townsend C, Cortina-Borja M, Thorne C. Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe. Antivir Ther. 2011; 16: 895-903. [Article]
  11. Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A for the EuroSIDA Study Group. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS. 2011; 25: 1305-1315. [PubMed]
  12. Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Paparizos V, Miro JM, Obel N, Prins M, Chêne G, Egger M. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T cell lymphocytes. Blood 2011; 117: 6100-8. [Article]
  13. Fox ZV, Cozzi-Lepri A, d'Arminio Monforte A, Karlsson A, Phillips AN, Kronborg G, Kjaer J, Clotet B, Lundgren JD for EuroSIDA. Predictors of having a resistance test following confirmed virological failure of cART: data from EuroSIDA. Antivir Ther 2011; 16: 781-5. [PubMed]
  14. Van der Helm J, Prins M, Del Amo J, Bucher H, Chêne G, Dorrucci M, Gill M J, Hamouda O, Sannes M, Porter K, Geskus R. The hepatitis C epidemic among HIV-positive men who have sex with men: incidence estimates from 1990 to 2007. AIDS 2011; 25: 1083-1091. [PubMed]
  15. Mussini C,  Cossarizza A, Sabin C,  Babiker A, De Luca A, Bucher H, Fisher M, Rezza G, Porter K, Dorrucci M. Decline of CD4+ T cell count before start of therapy and immunological response to treatment in antiretroviral-naïve individuals. AIDS 2011; 25: 1041-104. [PubMed]
  16. The Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warsawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chene G, Phillips A. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet 2011; 377: 1580-1587. [Article]
  17. Wittkop L, Günthard H, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kücherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, García F, Judd A, Porter K, Thiébaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G, for the EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363-371. [Article
  18. The PENPACT-1 (PENTA 9 / PACTG 390) Study Team, Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, Harper L, Harrison L, Hughes M, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS. First-line antiretroviral therapy initiation with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor combination and switch at higher versus low viral load in HIV-infected children: an open randomised controlled phase 2/3 trial. Lancet Infect Dis. 2011; 11: 273-283. [Article]
  19. Bannister W, Cozzi-Lepri A, Kjær J, Clotet B, Lazzarin A,  Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A; the EuroSIDA study group. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. J Antimicrob Chemother 2011; 66: 901-11. [Article]
  20. Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, Sambatakou H, Pedersen C, Lundgren JD, Kirk O; for the EuroSIDA study group. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: Results from the EuroSIDA study. HIV Clin Trials 2011; 12: 109-17. [Article]

Conference abstracts

  1. Soriano V on behalf of the EuroSIDA study. Hepatitis delta in HIV-infected individuals in Europe. 13th European AIDS Conference/EACS, Belgrade, October 2011. 
  2. Søgaard on behalf of the EuroSIDA study. The incidence of serious non-AIDS defining infections in the EuroSIDA cohort. 13th European AIDS Conference/EACS, Belgrade, October 2011.
  3. Peters L on behalf of the EuroSIDA study. Chronic hepatitis C (HCV) infection and chronic kidney disease (CKD) in HIV-infected patients in the EuroSIDA study. 13th European AIDS Conference/EACS, Belgrade, October 2011.
  4. Grint D, A Phillips on behalf of the EuroSIDA study.  Predictors of hepatitis C viremia in co-infected individuals. 13th European AIDS Conference/EACS, Belgrade, October 2011.
  5. Thorne C, Vigano A, Goetghebuer T, Alam N for the European Paediatric HIV and Lipodystrophy Study in EuroCoord. Components of metabolic syndrome in young adults with life-long HIV. 17-20 July 2011 IAS, Rome, Italy [Abstract]
  6. Podlekareva DN, Grint D, Panteleev A, Rakhmanova A, Miller R, Bruyand M, Furrer H, Post F, Zeltina I, Skrahin A, Miro JM, Obel N, Girardi E, Losso MH, Toibaro J, Caylá J, Lundgren JD, Kirk O, HIV/TB Collaboration Study Group. Mortality Rate, TB Recurrence and Causes of Death in HIV/TB Coinfected Patients: Results from the HIV/TB Collaborative Study. 13th European AIDS Conference/EACS, Belgrade, October 2011. [Presentation]
  7. Malyuta R, Semenenko I, Azhischeva H, Peters H, Thorne C for the Ukraine Paediatric HIV Cohort Study in EuroCoord. Children living with HIV in Ukraine: establishing a new paediatric cohort study. 3rd International Workshop on HIV Pediatrics, 17-20 July 2011 IAS, Rome, Italy [Abstract]
  8. Lodi S, d’Arminio Monforte A, del Amo J, Abgrall S, Sabin C, Porter K, Girardi E. Risk of tuberculosis following HIV seroconversion in low-burden tuberculosis countries. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, July 2011.[Abstract]
  9. Huang X, Lodi S, Fox Z, Phillips A, Johnson A, Porter K, Xu X and Wu H on behalf of the Beijin PRIMO cohort study and the CASCADE collaboration. Patterns of decrease in CD4 cell count after seroconversion: Comparison between Beijing PRIMO cohort and CASCADE seroconverter cohorts. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, July 2011. [Abstract]
  10. Judd A, Ene L, Goetghebuer T, Noguera A, Ramos JT, Thorne C, Duong T, Giaquinto C on behalf of the European Pregnancy and Paediatric HIV Cohort Collaboration in EuroCoord. Use and safety of fosamprenavir in HIV-infected children in the European Union: an ongoing post-marketing surveillance study. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, July 2011. [Abstract]
  11. Compagnucci A on behalf of the PENTA Steering Committee. Long term consequences of planned treatment interruptions in HIV infected children: Results from the TICCH (Treatment Interruption in Children with Chronic HIV-Infection) /PENTA 11 trial. 3rd International Workshop on HIV Pediatrics, 17-20 July 2011 IAS, Rome, Italy.Published in Reviews in Antiviral Therapy & Infectious Diseases 2011; 8: Abstract no. O_10, p.12. [Abstract]
  12. Heiner C. Bucher on behalf of the OI working group of COHERE. Risk of progression to AIDS or death in relation to CD4 cell levels in HIV-infected patients with sustained viral response to cART. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, July 2011. [Abstract]
  13. Van der Helm J, Prins M, del Amo J, Bucher H C, Chêne G, Dorrucci M, Gill M J, Hamouda O, Sannes M, Porter K, Geskus R B, on behalf of the CASCADE collaboration. The Hepatitis C epidemic among HIV-positive men who have sex with men: incidence estimates from 1990 to 2007. International Liver Congress 30 March- 3 April 2011 EASL, Berlin, Germany [Abstract]
  14. Touloumi G, Pantazis N, Chaix M L, Meyer L, Thiebaut R, Masquelier B, Kücherer C, d’Arminio Monforte A, Lodi S, Porter K, and CASCADE. Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE Collaboration. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 2011.
  15. Smit C, d'Arminio A, de Wolf F, Puoti M, Dabis F on behalf of the HCV working group of COHERE. HCV Treatment and CD4 Cell Count Decline in HIV/HCV Co-infected Patients: European Cohort Collaboration. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 2011. [Abstract]
  16. Kowalska JD, Mocroft A, Reekie J, Phillips A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Lundgren JD and Kirk O for the EuroSIDA study group. Risk of Cause-specific Deaths over Calendar Time and according to Cumulative Exposure to Combination Antiretroviral Therapy (cART). 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 2011. [Abstract]
  17. Cozzi-Lepri A, Paredes R, Phillips A, Kjær J, Lazzarin A, van Lunzen J, Karlsson A, Johnson M, and Lundgren J for the EuroSIDA study group. Predictors of Virologic Response to Etravirine-based cART Regimens in a Large European Cohort of HIV-infected Patients. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 2011. [Abstract]